Literature DB >> 32976668

Tumour size and overall survival among surgically treated patients with non-metastatic colon cancer in the U.S. Military Health System.

Melannie Alexander1,2, Jie Lin1,2,3,4, Craig D Shriver1,3, Katherine A McGlynn5, Kangmin Zhu1,2,3,4.   

Abstract

AIM: Larger tumour size and lymph node involvement traditionally predict poorer survival in colon cancer patients. However, it has been recently suggested that very small tumours (<5 mm) may be a predictor of poor prognosis in colon cancer patients when lymph nodes are involved. This study investigated whether node-positive colon cancer patients with small tumours had worse survival compared to those with larger tumours in the Department of Defense's (DoD) Military Health System (MHS), a universal health care system.
METHODS: Surgically treated colon cancer patients were identified from the DoD's Automated Central Tumour Registry (ACTUR). These patients were diagnosed with Stage I-III colon cancer between 1989 and 2010, had one or more lymph nodes examined, did not receive pre-operative radiotherapy and were followed through 2013 to determine vital status. Multivariable Cox models were used to examine survival differences according to tumour size, and data were stratified by lymph node status and age.
RESULTS: There were no differences in overall survival according to tumour size in the study population. These findings remained similar in analyses stratified by lymph node status and age.
CONCLUSION: In a universal healthcare system, small tumour size is not associated with worse prognosis in node-positive colon cancer patients.
© 2020 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  colon cancer; military health system; survival; tumour size; universal health care

Mesh:

Year:  2020        PMID: 32976668      PMCID: PMC8573790          DOI: 10.1111/codi.15381

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.917


  11 in total

1.  Guidelines 2000 for colon and rectal cancer surgery.

Authors:  H Nelson; N Petrelli; A Carlin; J Couture; J Fleshman; J Guillem; B Miedema; D Ota; D Sargent
Journal:  J Natl Cancer Inst       Date:  2001-04-18       Impact factor: 13.506

2.  Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer.

Authors:  Jennifer Y Wo; Kun Chen; Bridget A Neville; Nancy U Lin; Rinaa S Punglia
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

3.  Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.

Authors:  Hans-Joachim Schmoll; Chris Twelves; Weijing Sun; Michael J O'Connell; Thomas Cartwright; Edward McKenna; Muhammad Saif; Steve Lee; Greg Yothers; Daniel Haller
Journal:  Lancet Oncol       Date:  2014-11-12       Impact factor: 41.316

4.  Breast cancer-specific mortality in small-sized tumor with node-positive breast cancer: a nation-wide study in Korean breast cancer society.

Authors:  Jai Min Ryu; Hyouk Jin Lee; Tae In Yoon; Eun Sook Lee; Soo Jung Lee; Jin Hyang Jung; Byung Joo Chae; Seok Jin Nam; Jeong Eon Lee; Se Kyung Lee; Soo Youn Bae; Jonghan Yu; Seok Won Kim
Journal:  Breast Cancer Res Treat       Date:  2016-09-02       Impact factor: 4.872

5.  Association Between Very Small Tumor Size and Increased Cancer-Specific Mortality in Node-Positive Colon Cancer.

Authors:  Vinayak Muralidhar; Ryan D Nipp; David P Ryan; Theodore S Hong; Paul L Nguyen; Jennifer Y Wo
Journal:  Dis Colon Rectum       Date:  2016-03       Impact factor: 4.585

6.  Tumor size predicts long-term survival in colon cancer: an analysis of the National Cancer Data Base.

Authors:  Sukamal Saha; Mohammed Shaik; Gregory Johnston; Supriya Kumar Saha; Lindsay Berbiglia; Micheal Hicks; Jill Gernand; Sandeep Grewal; Madan Arora; David Wiese
Journal:  Am J Surg       Date:  2014-12-23       Impact factor: 2.565

7.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

Authors:  Thierry André; Corrado Boni; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Andrea Bonetti; Philip Clingan; John Bridgewater; Fernando Rivera; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

8.  The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Treatment of Colon Cancer.

Authors:  Jon D Vogel; Cagla Eskicioglu; Martin R Weiser; Daniel L Feingold; Scott R Steele
Journal:  Dis Colon Rectum       Date:  2017-10       Impact factor: 4.585

9.  Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer.

Authors:  Vinayak Muralidhar; Ryan D Nipp; Harvey J Mamon; Rinaa S Punglia; Theodore S Hong; Cristina Ferrone; Carlos Fernandez-Del Castillo; Aparna Parikh; Paul L Nguyen; Jennifer Y Wo
Journal:  Ann Surg Oncol       Date:  2018-10-08       Impact factor: 5.344

10.  Value of tumor size as a prognostic variable in colorectal cancer: a critical reappraisal.

Authors:  Peter Kornprat; Marion J Pollheimer; Richard A Lindtner; Andrea Schlemmer; Peter Rehak; Cord Langner
Journal:  Am J Clin Oncol       Date:  2011-02       Impact factor: 2.339

View more
  1 in total

1.  Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival.

Authors:  Olatunji B Alese; Wei Zhou; Renjian Jiang; Katerina Zakka; Zhonglu Huang; Chimuanya Okoli; Walid L Shaib; Mehmet Akce; Maria Diab; Christina Wu; Bassel F El-Rayes
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.